tbuckley/cabot-search huggingface dataset:
Inhibition of the NAMPT-Triggered Deacetylation of HCLS1 Protein: A New Therapeutic Option in Chronic Myeloid Leukemia
Authors: Bardia Samareh, Inna Zimmer, Andrew Zikic, Olga Klimenkova, Houra Loghmani-Khouzani, Meinolf Suttorp, Lothar Kanz, Karl Welte, Julia Skokowa
Journal: Blood (2015)
P3.02b-103 Identification of On-Target Mechanisms of Resistance to EGFR Inhibitors Using ctDNA Next-Generation Sequencing
Authors: Jessica Lin, Stephen Fairclough, Rebecca Nagy, Shirish Gadgeel, Matthew Gubens, Balazs Halmos, Suresh Ramalingam, Richard Lanman, Alice Shaw
Journal: Journal of Thoracic Oncology (2017)
Impact on Transplant Outcome of Karyotyping Analysis in Apheresis Products for Autologous PBSC Transplantation in De Novo Acute Leukemias (AL).
Authors: Bertrand Delannoy, Franck E. Nicolini, Quoc-Hung Le, Gilles Clapisson, Irene Philip, Nicole Raus, Isabelle Tigaud, Christiane Charrin, Xavier Thomas, Youcef Chelghoum, Emmanuelle Tavernier, Veronique Lheritier, Mauricette Michallet
Journal: Blood (2004)
Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
Authors: T Olofsson, I F Petersson, J K Eriksson, M Englund, J A Nilsson, P Geborek, L T H Jacobsson, J Askling, M Neovius
Journal: Annals of the Rheumatic Diseases (2017)

To examine predictors of work ability gain and loss after anti-tumour necrosis factor (TNF) start, respectively, in working-age patients with rheumatoid arthritis (RA) with a special focus on disease duration.Patients with RA, aged 19-62 years, starting their first TNF inhibitor 2006-2009 with full work ability (0 sick leave/disability pension days during 3 months before bio-start; n=1048) or no work ability (90 days; n=753) were identified in the Swedish biologics register (Anti-Rheumatic Treatment In Sweden, ARTIS) and sick leave/disability pension days retrieved from the Social Insurance Agency. Outcome was defined as work ability gain ≥50% for patients without work ability at bio-start and work ability loss ≥50% for patients with full work ability, and survival analyses conducted. Baseline predictors including disease duration, age, sex, education level, employment, Health Assessment Questionnaire, Disease Activity Score 28 and relevant comorbidities were estimated using Cox regression.During 3 years after anti-TNF start, the probability of regaining work ability for totally work-disabled patients was 35% for those with disease duration <5 years and 14% for disease duration ≥5 years (adjusted HR 2.1 (95% CI 1.4 to 3.2)). For patients with full work ability at bio-start, disease duration did not predict work ability loss. Baseline disability pension was also a strong predictor of work ability gain after treatment start.A substantial proportion of work-disabled patients with RA who start anti-TNF therapy regain work ability. Those initiating treatment within 5 years of symptom onset have a more than doubled 3-year probability of regaining work ability compared with later treatment starts. This effect seems largely due to the impact of disease duration on disability pension status.
P84 The relationship between unadjusted referral to treatment times, disease stage and survival in lung cancer
Authors: SA Hodgson, KG Blyth
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Cancer waiting times (CWT) targets have helped hospital services evolve to meet the needs of Lung Cancer patients. However, these outcomes are adjusted to allow for perceived clinical complexity or deviation from a ‘standard’ diagnostic journey. Few patients breach CWT targets in our unit. We performed a retrospective audit to determine the actual time our patients spent on diagnostic pathways and how this related to disease stage and survival. <h3>Methods</h3> 377 consecutive patients who presented with Lung Cancer during 2013 were identified from our MDT database. 243/377 (64%) presented as an inpatient and were excluded. 22/134 GP referrals were excluded (insufficient records, aborted investigation (clinical deterioration, patient preference), incomplete staging) leaving 112 cases. Demographics, histology, referral-to-treatment (RTT), referral-to-diagnosis (RTD) and diagnosis-to-treatment (DTT) times were recorded. Overall Survival (OS) based on RTT times and Stage was assessed using Kaplan-Meier methodology. <h3>Results</h3> 82/112 (73.2%) patients had non-small cell lung cancer, 18 (16.1%) had small cell lung cancer and 12 (10.7%) were radiologically-diagnosed. 48/112 patients (42.9%) had stage I to IIIA disease. Mean RTD, RTT and DTT times were 43 (SD 55), 69 (SD 45) and 26 (SD 51) days, respectively. RTD time was &lt;31 days in 57/112 cases (50.8%). 31.6% of these were Stage I-IIIA, compared with 54.5% Stage I-IIIA when RTD was &gt;31 days. RTT time was &lt;62 days in 59/112 cases (52.7%). 25.4% of these were Stage I-IIIA, compared with 62.3% Stage I-IIIA when RTT was &gt;62 days. RTT time was &lt;62 days in 15/48 (31.3%) Stage I-IIIA patients and &lt;62 days in 44/64 (68.8%) patients with Stage IIIB-IV. <h3>Conclusions</h3> Despite few CWT breachers, RTT times were frequently &gt;62 days suggesting pathway adjustments have a major impact. Patients with earlier stage disease, and the most to lose from diagnostic delay had longer diagnostic journeys. The survival disadvantage of short pathways likely reflects stage mix. Pathway redesign to accelerate the complex diagnostics needed for radically-treatable disease should be considered. CWT adjustments may have unintentionally clouded this issue.
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
Authors: Daniela Massihnia, Amir Avan, Niccola Funel, Mina Maftouh, Anne van Krieken, Carlotta Granchi, Rajiv Raktoe, Ugo Boggi, Babette Aicher, Filippo Minutolo, Antonio Russo, Leticia G. Leon, Godefridus J. Peters, Elisa Giovannetti
Journal: Journal of Hematology & Oncology (2017)

There is increasing evidence of a constitutive activation of Akt in pancreatic ductal adenocarcinoma (PDAC), associated with poor prognosis and chemoresistance. Therefore, we evaluated the expression of phospho-Akt in PDAC tissues and cells, and investigated molecular mechanisms influencing the therapeutic potential of Akt inhibition in combination with gemcitabine. Phospho-Akt expression was evaluated by immunohistochemistry in tissue microarrays (TMAs) with specimens tissue from radically-resected patients (n = 100). Data were analyzed by Fisher and log-rank test. In vitro studies were performed in 14 PDAC cells, including seven primary cultures, characterized for their Akt1 mRNA and phospho-Akt/Akt levels by quantitative-RT-PCR and immunocytochemistry. Growth inhibitory effects of Akt inhibitors and gemcitabine were evaluated by SRB assay, whereas modulation of Akt and phospho-Akt was investigated by Western blotting and ELISA. Cell cycle perturbation, apoptosis-induction, and anti-migratory behaviors were studied by flow cytometry, AnnexinV, membrane potential, and migration assay, while pharmacological interaction with gemcitabine was determined with combination index (CI) method. Immunohistochemistry of TMAs revealed a correlation between phospho-Akt expression and worse outcome, particularly in patients with the highest phospho-Akt levels, who had significantly shorter overall and progression-free-survival. Similar expression levels were detected in LPC028 primary cells, while LPC006 were characterized by low phospho-Akt. Remarkably, Akt inhibitors reduced cancer cell growth in monolayers and spheroids and synergistically enhanced the antiproliferative activity of gemcitabine in LPC028, while this combination was antagonistic in LPC006 cells. The synergistic effect was paralleled by a reduced expression of ribonucleotide reductase, potentially facilitating gemcitabine cytotoxicity. Inhibition of Akt decreased cell migration and invasion, which was additionally reduced by the combination with gemcitabine. This combination significantly increased apoptosis, associated with induction of caspase-3/6/8/9, PARP and BAD, and inhibition of Bcl-2 and NF-kB in LPC028, but not in LPC006 cells. However, targeting the key glucose transporter Glut1 resulted in similar apoptosis induction in LPC006 cells. These data support the analysis of phospho-Akt expression as both a prognostic and a predictive biomarker, for the rational development of new combination therapies targeting the Akt pathway in PDAC. Finally, inhibition of Glut1 might overcome resistance to these therapies and warrants further studies.
Effect of Novel Agents on Stem Cell (SC) Mobilization and Engraftment In Patients with Multiple Myeloma (MM) at Memorial Sloan-Kettering Cancer Center
Authors: Melissa Pozotrigo, Nelly G. Adel, Vincent LaRussa, Xiaoshe Chen, Elyn Riedel, Lilian Reich, Heather Landau, Sergio Giralt, Hani Hassoun
Journal: Blood (2010)
Occupy EGFR
Authors: Jin H. Park, Mark A. Lemmon
Journal: Cancer Discovery (2012)

Abstract Erlotinib and gefitinib inhibit the growth of non–small cell lung cancer tumors that harbor activating epidermal growth factor receptor (EGFR) mutations but are ineffective against EGFR variants found in glioblastoma. New studies by Barkovich and colleagues and Vivanco and colleagues show that these drugs only occupy the active sites of glioblastoma-derived EGFR mutants to a limited extent and fail to inhibit the activated receptor. Other EGFR inhibitors that target distinct receptor conformations are more effective in the treatment of glioblastoma. These studies reveal distinct drug selectivities for different EGFR mutations and show that an analysis of binding-site occupancy should be considered as a biomarker for inhibitor efficacy in targeting EGFR. Cancer Discov; 2(5); 398–400. ©2012 AACR. Commentary on Barkovich et al., p. 450 and Vivanco et al., p. 458.
Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS)
Authors: Cihan Ay, Rainer Vormittag, Daniela Dunkler, Ralph Simanek, Alexandru-Laurentiu Chiriac, Johannes Drach, Peter Quehenberger, Oswald Wagner, Christoph Zielinski, Ingrid Pabinger
Journal: Blood (2008)
Aberrant DNA Methylation and Transcriptional Silencing of DLC-1 in Waldenstrom's Macroglobulinemia.
Authors: Lian Xu, Bryan Ciccarelli, Evdoxia Hatjiharissi, Guang Yang, Yangsheng Zhou, Zachary Hunter, Jenny Sun, Ping Gong, Xia Liu, Hsiuyi Tseng, Thea Ioakimidis, Robert Manning, Christina Hanzis, Yang Cao, Megan Lewicki, Christopher J Patterson, Steven Treon
Journal: Blood (2009)
P191 Reducing the carbon footprint in a regional long term ventilation service with the use of remote monitoring
Authors: R Moses, C Taylor, S Wood, A Vyas
Journal: Thorax (2016)

<h3>Introduction</h3> There is strong emerging evidence on the devastating effect of anthropogenic climate change on lung health. In England, the NHS accounts for 30% of the public sector carbon footprint, with patient travel being accountable for 8% of overall travel (17%). The climate change act (2008) resulted in the government and NHS committing to an 80% reduction in carbon emissions by 2050. <h3>Methods</h3> There are many studies detailed the benefit of telemonitoring in reducing carbon footprint within NHS services. Within the Lancashire and South Cumbria Long Term Ventilation Service (LSCLTVS) we have invested in a ventilator remote monitoring system (Encore<i>Anywhere</i><sup>TM</sup>). Over a 3 month time period we analysed the telephone consultations of all 138 patients under the care of the LSCLTVS (80 patients on remote monitoring systems). Patients or carers that called reporting deterioration in a clinical condition that could not be rectified over the telephone were identified. The normal intervention that would follow would be a visit from the GP or community respiratory team, hospital admission, clinic visit or home visit from the ventilation team. A ventilator review was indicated in 29 patients which would normally necessitate either a clinic visit to Royal Preston Hospital or a consultation at home. However as these patients had remote ventilator monitoring we were able to review data and make changes remotely. <h3>Results</h3> In a 3 month time period 29 return journeys were prevented through the use of remote monitoring. This equated to 1029.3 km (623 miles), 249 kgCO<sub>2</sub>e (0.24 t CO<sub>2</sub>e)*saved over 28 hours in commuting time and £255 in mileage costs (40 p per mile). It also had a positive impact on patient experience and no hospital admissions or clinic visits were necessary after remote consultation. 62% (n = 18) patients required use of rescue packs including antibiotics and mucolytics as well as remote ventilator changes. *Emission factors from DEFRA 2012 show for an average petrol car the value is 0.24234 kg CO<sub>2</sub>e per km <h3>Discussion</h3> The use of remote monitoring within the LSCLTVS has reduced the carbon footprint of the service on average 6.6 kg CO<sub>2</sub>e per patient. Patients also reported improved satisfaction and compliance.
Ruxolitinib in Combination with Orally Etoposide and Corticosteroids (REC) Is Safe and Effective in Heavily Pretreated Hodgkin and Non-Hodgkin Lymphomas
Authors: Anne Parcelier, Pierre Morel, Bruno Royer, Caroline Delette, Isabelle Leduc, Henri Sevestre, Jean-Pierre Marolleau
Journal: Blood (2015)
Retrospective Analysis on 290 Patients with Polycythemia Vera Referred to a Single Transfusion Centre: Diagnosis Revision According to WHO Criteria and Evaluation of Survival and Complications According to Prognostic Factors and Treatment
Authors: Ermanno Venturino, Dario Ferrero, Elena Crisà, Mario Bazzan, Ausilia Ciocca, Roberto Sorasio, Valentina Giai, Mariella Genuardi, Mario Boccadoro
Journal: Blood (2008)
Traumatic Brain and Spinal Cord Fatalities Among High School and College Football Players — United States, 2005–2014
Authors: Kristen L. Kucera, Rebecca K. Yau, Johna Register-Mihalik, Stephen W. Marshall, Leah C. Thomas, Susanne Wolf, Robert C. Cantu, Frederick O. Mueller, Kevin M. Guskiewicz
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

An estimated 1.1 million high school and 75,000 college athletes participate in tackle football annually in the United States. Football is a collision sport; traumatic injuries are frequent (1,2), and can be fatal (3). This report updates the incidence and characteristics of deaths caused by traumatic brain injury and spinal cord injury (4) in high school and college football and presents illustrative case descriptions. Information was analyzed from the National Center for Catastrophic Sport Injury Research (NCCSIR). During 2005-2014, a total of 28 deaths (2.8 deaths per year) from traumatic brain and spinal cord injuries occurred among high school (24 deaths) and college football players (four deaths) combined. Most deaths occurred during competitions and resulted from tackling or being tackled. All four of the college deaths and 14 (58%) of the 24 high school deaths occurred during the last 5 years (2010-2014) of the 10-year study period. These findings support the need for continued surveillance and safety efforts (particularly during competition) to ensure proper tackling techniques, emergency planning for severe injuries, availability of medical care onsite during competitions, and assessment that it is safe to return to play following a concussion.
Expression of Coagulation FVIII and FIX in Human Adipose Stromal Cells (hASC) and hASC-Derived Cells - Potential Autologous Cell Therapy for Hemophilia.
Authors: Elliot D. Rosen, Zhong Liang, Hui Song, Daniella Bischoff, Malgorzata Kamocka, Amy Zollman
Journal: Blood (2007)
MA03.05 Cost Effectiveness Analysis of CT vs Chest X-Ray (CXR) vs No Screening for Lung Cancer (LC) in the PLCO and NLST Randomized Population Trials (RPTs)
Authors: John Paul Flores, Alejandro Moreno-Koehler, Matthew Finkelman, Jaime Caro, Gary Strauss
Journal: Journal of Thoracic Oncology (2017)
Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome
Authors: Laurence A. Greenbaum, Yahsou Delmas, Fadi Fakhouri, John F. Kincaid, Christoph Licht, Enrico E. Minetti, Chris Mix, Francois Provôt, Eric Rondeau, Neil Sheerin, Jimmy Wang, Laurent E. Weekers, Jan Menne
Journal: Blood (2015)
Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization
Authors: Maurizio Di Liberto, Xiangao Huang, Jamieson Bretz, Scott A Ely, Rediet Zewdu, David Jayabalan, Suzhen Chen, Christopher J Kirk, Sophia Randolph, Ruben Niesvizky, Selina Chen-Kiang
Journal: Blood (2010)
IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia
Authors: Karen R Rabin, Clinton C Mason, Sivashankarappa Gurusiddappa, Hon-Chiu Eastwood Leung, Debra J. Morrison, Deepa Bhojwani, Phillip Barnette, Sarah T. South, Rodney R. Miles, Meenakshi Devidas, Andrea Pession, Giuseppe Basso, Nicola E Potter, Lyndal Kearney, Anthony V. Moorman, Susana C. Raimondi, Sima Jeha, Ching-Hon Pui, William L. Carroll, Mignon L. Loh, Stephen P. Hunger, Charles G Mullighan, Joshua D. Schiffman
Journal: Blood (2012)
P2.04-027 Targeting Adenosine A2B Receptor for Modulation of Tumor Microenvironment, Primary Tumor Growth, and Lung Metastasis
Authors: Jason Evans, Andrey Bobko, Stephanie Lewis, Charles Martin, Mohammed Rahman, Sara Cole, Anwari Akhter, Anneliese Antonucci, David Carbone, Elena Tchekneva, Valery Khramtsov, Mikhail Dikov
Journal: Journal of Thoracic Oncology (2017)
P2.03a-030 nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Interim Quality of Life (QoL) Results From ABOUND.sqm
Authors: Michael Thomas, Ray Page, Laurent Gressot, Davey Daniel, Daniel Morgensztern, Victoria Villaflor, Santiago Aix, Teng Ong, Nataliya Trunova, David Spigel
Journal: Journal of Thoracic Oncology (2017)
P3.02c-029 Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab
Authors: Shawn Kothari, Stephen Bagley, Charu Aggarwal, Joshua Bauml, Evan Alley, Tracey Evans, John Kosteva, Christine Ciunci, Jeffrey Thompson, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Beth Eaby-Sandy, Faith Mutale, Gloria Dilullo, Roger Cohen, Anil Vachani, Corey Langer
Journal: Journal of Thoracic Oncology (2017)
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with early breast cancer
Authors: S. Iacobelli, E. Cianchetti, C. Ficorella, D. Angelucci, S. Grossi, E. Ricevuto, G. Castrilli, M. Zilli, N. Tinari, C. Natoli
Journal: Journal of Clinical Oncology (2006)

10598 Background: The use of preoperative chemotherapy for breast cancer has been shown to result in similar disease-free and overall survival as postoperative adjuvant chemotherapy. Additionally, the rate of pathologic complete response (pCR) in the breast after preoperative chemotherapy has been shown to correlate with survival. The objective of this study was to evaluate the activity and safety of a dose-dense and sequential chemotherapy of epirubicin/cyclophosphamide (EC) followed by docetaxel/capecitabine (DXe) given preoperatively in patients with early breast cancer not candidate to breast-conserving surgery. Methods: Forty-one women with histologically/cytologically confirmed primary breast cancer (T2–3, N0–2, M0) received 4 cycles of EC (cyclophosphamide, 600 mg/m 2 and epirubicin, 90 mg/m 2 ) q2 weeks followed by two cycles of DXe (docetaxel, 36 mg/m 2 days 1, 8, and 15 and capecitabine, 1250 mg/m 2 days 5–18) q 28 days, with pegfilgrastim support. The study was designed as a Simon’s two-step phase II study. The primary end point of the study was the incidence of pCR defined as the absence of invasive cancer in the breast at definitive surgery. Results: Thirty-nine out of 41 enrolled patients were evaluable for response to treatment (one patient withdrew from the study for G4 neutropenia after the first EC cycle, and the other for therapy refusal after the 4 EC cycles). A pCR was observed in 10 patients for a total pCR rate of 25.6%. Interestingly, all but one of the 10 pCR cases showed ER/PR-negative/Her2-positive tumors. A clinical response (CR or PR) detected by palpation and by imaging was observed in 37 patients, for an overall response rate of 95%. Twenty-nine patients (75%) underwent breast-conserving surgery. The treatment was well tolerated: one patient experienced G3 mucositis and another patient required a 25% dose reduction of capecitabine because of hand-foot syndrome. There was no case of cardiac toxicity, thrombocytopenia or any other serious adverse event. Conclusions: The dose-dense sequential combination EC/DXe is endowed with good antitumor activity and limited toxicity, allowing a high rate of pCR and breast conservation. Thus, this regimen can be considered for further clinical trial. No significant financial relationships to disclose.
Norwegian patients and retail chicken meat share cephalosporin-resistant Escherichia coli and IncK/ bla CMY-2 resistance plasmids
Authors: E.S. Berg, A.L. Wester, J. Ahrenfeldt, S.S. Mo, J.S. Slettemeås, M. Steinbakk, Ø. Samuelsen, N. Grude, G.S. Simonsen, I.H. Løhr, S.B. Jørgensen, S. Tofteland, O. Lund, U.R. Dahle, M. Sunde
Journal: Clinical Microbiology and Infection (2017)
Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies.
Authors: Pellegrino Musto, Potito Rosario Scalzulli, Lorella Melillo, Michele Nobile, Matteo Dell’Olio, Antonio La Sala, Saverio Mantuano, Carlo Bodenizza, Antonietta Falcone, Grazia Sanpaolo, Angelo Michele Carella, Michele Mario Greco, Germana Beltrami, Nicola Cascavilla
Journal: Blood (2004)